Abstract: Disclosed herein are methods and apparatuses for the safe, high-yield collection of sterile amniotic fluid. The apparatus are configured to allow sufficient flexibility for the device to gain access to all areas of the amniotic cavity, to allow sufficient stiffness for the amniotic fluid collection device to puncture the amniotic and chorionic membranes, yet allow sufficient suppleness to pose no significant risk of maternal or fetal harm. Further disclosed are cells isolated from the full-term amniotic fluid, and methods for using, reprogramming, and differentiating these cells.

Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.

Abstract: The present invention belongs to a pharmaceutical composition preparation field of traditional Chinese medicine, and more particularly relates to a pharmaceutical composition for treating AIDS and preparation method thereof. The pharmaceutical composition of the present invention for treating AIDS comprises the following raw medicinal materials: Cordyceps Sinensis in an amount of 3-6 parts by weight, Dried Radix Rehmanniae in an amount of 4-12 parts by weight, Mylabris in an amount of 1-3 parts by weight, and Rhizoma Anemarrhenae in an amount of 3-6 parts by weight. The clinical trials show that the pharmaceutical composition has a relatively good therapeutic effect for treating AIDS.

Abstract: The present invention discloses a novel antitumour agent which provides an antitumour activity based on metabolites with reduced side effects. Moreover, the antitumour agent is prepared starting with a highly safe bacterium used in food production, which is a probiotic lactic acid bacterium.

Abstract: A composition is provided comprising extracts of at least grape seeds (GSE) and green tea. The extracts are preferably polyphenolic and preferably comprises probiotic bacteria. The use of extracts from green tea and grape seeds for the manufacture of a medicament against a neurodegenerative disease is also disclosed.

Abstract: Provided are therapeutic compositions containing combinations of bacteria, for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for use thereof.

Abstract: Embodiments are directed to methods and composition for preparing and using therapeutic phage.

Abstract: The present disclosure provides viral microparticles comprising genetically-engineered baculoviruses (at least partially) embedded in a polymeric matrix for the local delivery of therapeutic nucleic acid molecules to the cells of a vertebrate individual (optionally in combination with a medical implant such as vascular stent platform). The viral microparticles are especially useful for promoting the healing of a wound as well as the repair of a blood vessel and prevent pathological scarring. Also provided herein are processes for making the viral microparticles, pharmaceutical compositions comprising viral microparticles as well as supports comprising the viral microparticles for the locating the viral microparticles in a wound or in the vicinity of a wound.

Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.

Abstract: The invention relates to herbal compositions having standalone preparations of two phytochemicals, Bakuchiol and Boswellic acid as well as synergistic combinations of Bakuchiol with either Boswellia oil or boswellic acid or both. Bakuchiol in these compositions has assay by HPLC of greater than 50%, whereas boswellic acid is standardized to at least 20% of 3-o-Acetyl-11-keto-beta-boswellic acid. The compositions are either oral—for relief and remission of proliferative skin disorders or topical—for the treatment and management of pain. The invention further provides process of preparation of these compositions. The invention also relates to use of the compositions for treating pain or proliferative skin disorders and various dosage regimens.

Abstract: A composition comprising a standardized amount of a schisandrin compound and methods for production thereof for use in reducing stress, increasing blood antioxidant level, reducing lipid peroxidation and/or improving symptoms of depression in subjects in need thereof.

Abstract: The invention relates to a composition for pharmaceutical or nutritional or cosmetic use, formulated for oral or topical use and possessing antioxidant activity against free radicals, comprising: a) a Vitis vinifera seed, or seed and leaf, extract containing a combination of the flavonoids catechin and quercetin in a molar ratio in a range from 6:1 to 3:1, respectively, or a?) a Vitis vinifera seed, or seed and leaf, extract containing a combination of the flavonoids catechin and quercetin in a molar ratio in a range from 7:1 to 4:1, respectively, or a?) a mixture of Vitis vinifera extracts a) and a?), or a??) a mixture of catechin and quercetin in a molar ratio in a range from 7:1 to 3:1, respectively, together with b) an olive, Olea europaea L, leaf extract having a hydroxytyrosol content in a range from 1% to 30% by weight of the extract, or b?) hydroxytyrosol in an amount equal to that contained in the b) extract.

Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).

Abstract: An eye health supplement administered to a person in order to prevent and treat eye-related conditions or diseases. The eye health supplement focuses on treating conditions and diseases, such as diabetic retinopathy, macular degeneration, hypertensive retinopathy, keratoconjunctivitis sicca, and more, and the underlying symptoms of eye-related conditions and diseases through the inclusion of a quantity of birch leaf powder, a quantity of pomegranate, a quantity of garlic bulb powder, a quantity of fenugreek powder, a quantity of curcumin, a quantity of asthaxanthin, a quantity of bilberry extract powder, and a quantity of glutathione powder. The quantity of birch leaf powder, the quantity of pomegranate, the quantity of garlic bulb powder, the quantity of fenugreek powder, the quantity of curcumin, the quantity of asthaxanthin, the quantity of bilberry extract powder, and the quantity of glutathione powder are heterogeneously mixed into a supplement mixture for oral or transdermal administration.

Abstract: The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging.

Abstract: Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the pharmaceutical composition reverses recent onset Type 1 Diabetes (T1D). Also described is a method for identifying an individual who will be responsive to this treatment. In addition there is described a device containing the pharmaceutical composition for injecting the pharmaceutical composition into the celiac artery.

Abstract: A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In certain embodiments, the self assembling materials are peptidomimetics, nucleotidomimetics, di- and triblock copolymers, N-alkylacrylamides, or dendimers. These materials are also useful in a method for regeneration or repair of tissue or cells forming tissue.

Abstract: The present invention relates to the use of a combination of an anti-retroviral agent such as zidovudine and an anti-microbial agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anti-retroviral agent such as zidovudine and an anti-microbial agent for the treatment of microbial infections.

Abstract: Provided herein are methods for identifying a cancer patient at risk for resistance to an HDAC inhibitor therapy, comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in the sample; quantifying a level of the TSPYL5 expression in the sample, wherein a high level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, correlates with resistance to the HDAC inhibitor therapy; and applying the correlation to identify the cancer patient at risk for resistance to the HDAC inhibitor therapy.

Abstract: Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.

Abstract: Methods of treating Alzheimer's disease and other tauopathies are disclosed. In particular, the invention relates to methods of treating Alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase (MARK). Hyperphosphorylation of tau by MARK is associated with the pathogenic deposition of intracellular neurofibrillary tangles and loss of synaptic markers, dendritic spines, and synapses during progression of Alzheimer's disease and other tauopathies. Peptide inhibitors derived from the Helicobacter pylori protein CagA block phosphorylation of tau in neuronal cells and thereby decrease the deposition of neurofibrillary tangles and the toxic effects of Abeta-42.

Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.

Abstract: The present invention relates to the treatment of patients with pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.

Abstract: The present invention provides a method of treating a subject suffering from a fatty liver disease which comprises administering to the subject a Notch decoy protein or Jagged inhibitor in an amount effective to treat the subject's fatty liver disease. The present invention provides a composition comprising a pharmaceutically acceptable carrier and an amount of a Notch decoy protein or Jagged inhibitor effective to treat a fatty liver disease. The present invention provides a package comprising: (a) the pharmaceutical composition of the invention and (b) instructions for using the pharmaceutical composition of step (a) to treat the fatty liver disease.

Abstract: The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.

Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.

Abstract: The invention relates to the use of a peptide which binds to lipopolysaccharide (LPS) or lipoteichoic acid (LTA), for manufacturing a pharmaceutical composition for treating sepsis or septic shock, wherein the peptide comprises the amino acid sequence of apolipoprotein CI (apoCI) or a part thereof that comprises at least the amino acids of the C-terminal helix of apoCI. The use of human apoCI is preferred. The peptide can be administered clinically to patients who have sepsis or threaten to develop sepsis. Measurement of the apoCI content in blood can be utilized for determining the severity and prognosis of the course of the septic condition or for monitoring an anti-sepsis treatment.

Abstract: Provided herein are methods, assays and compositions relating to the treatment of neurological diseases and disorders, particularly by modulating expression and/or activity of Bif-1.

Abstract: The present disclosure provides methods of inhibiting viral activity in a cell, the methods generally involving contacting the cell with a soluble CD137 polypeptide or a FAM3C polypeptide. The present disclosure provides methods for treating a virus infection in an individual, the methods generally involving administering to the individual an effective amount of a soluble CD137 polypeptide or a FAM3C polypeptide.

Abstract: The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms. PACAP, alone or combined with an antiviral molecule, demonstrated its effectiveness by increasing the survival of fish or crustaceans infected by viruses when it was administered orally, by injection or by immersion baths. Furthermore, it was observed that treated organisms keep or increase its weight as compared to infected and non-treated organisms. PACAP or PACAP-containing combinations decreased the viral load in tissues and organs susceptible to viral infections as it was determined by RT-PCR.

Abstract: Disclosed herein are novel and improved preparations and methods for manufacturing substantially liquid preparations of recombinant human insulin API. The purified recombinant human insulin Active Pharamaceutical Ingredient (API) preparations are substantially free of by-products associated with the lyophilization and/or crystallization. The methods for manufacturing the substantially liquid recombinant human insulin API preparations are provided with optional steps for subjecting the recombinant insulin preparation to lyophilization and/or crystallization. Enhanced yield of recombinant insulin of greater purity are thereby provided according to the present invention. Highly purified formulations of recombinant human insulin of the API insulin preparations disclosed herein are also provided. Stably transformed E.

Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

Abstract: The present invention is directed to kit, drug combinations and methods for promoting endogenous bone marrow (BM)-derived vasculogenic progenitor cell (PC) mobilization, sensitization of such cells and chemotaxis to the site of an injury such as injuries associated with osteointegration of implants and associated soft tissues, fat grafting and endochondral bone injuries and disease.

Abstract: A nose bleed treatment system for use in treating a patient having a nose bleed uses a nose clip that resiliently clamps the patient's nostrils to provide pressure to help stop the bleeding. A medically effective agent is sprayed in the patient's nostril using a spray bottle that has an elongated tip to apply the agent close to the source of the bleed. The medically effective agent contains at least one of a clot enhancing agent and a vasoconstricting agent. The agent may contain vitamin K as well as a vasoconstricting agent epinephrine with pytonadione (vitamin K1), menaquinone (vitamin K2), menadion (vitamin K3) fibrogen or other suitable medications. The medically effective agents are preferably herbally or mammalian sourced.

Abstract: Provided are liquid and lyophilized recombinant Factor VIII formulations, including formulations for polymer-conjugated FVIII such as PEGylated Factor VIII.

Abstract: A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.

Abstract: IL-2 fusion toxins, e.g., bivalent-IL2 fusion toxins, and methods of use thereof.

Abstract: The present invention provides compositions and methods for treating stroke. The invention relates to inhibiting the level and/or activity of cell debris after the onset of stroke. In certain embodiments, the invention provides for the catabolism or inhibition of at least one of extracellular RNA, extracellular DNA, and extracellular ATP.

Abstract: Aciduliprofundum boonei glycosyl hydrolase 25 (GH25) muramidase is shown here to exhibit antibacterial activity against several distinct bacterial families. Formulations and methods of use for this GH25 are provided.

Abstract: This disclosure relates to composition and methods for improving blood clotting in a subject that developed anti-factor VIII antibodies. In certain embodiments, this disclosure contemplates a conjugate comprising a toxin, e.g., ricin, abrin, saporin, coupled to factor VIII or functional variant thereof either through a linking group or as a fusion protein.

Abstract: The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a phytosterol and/or phytostanol or ester thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and a phytosterol and/or phytostanol or ester thereof. The invention also relates to the combination of a broccoli extract or powder and a phytosterol and/or phytostanol or ester thereof. The invention provides compositions and methods relating to these combinations.

Abstract: Disclosed are bacterial toxins and uses thereof as specific proteases for Ras sarcoma oncoproteins (Ras proteins). The bacterial toxins may be modified for use as pharmaceutical agents for treating Ras-dependent diseases and disorders including cell proliferation diseases and disorders such as cancer.

Abstract: Use of erythrocytes containing arginine deirainase for the preparation of a medicinal product for lowering the plasma concentration of arginine in vivo. The use relates in particular to the treatment of arginine-dependent tumors, such as hepatocarcinoma and malignant melanoma, or inhibition of the synthesis of nitric oxide, and the prevention and/or treatment of septic shock.

Abstract: The invention features isolated polypeptides and conjugates including the amino acid sequence of any one of SEQ ID NOs: 3-11, or a variant sequence thereof having up to three substitutions, deletions, or additions to the amino acid sequence of any one of SEQ ID NOs: 3-11, wherein the polypeptide does not include more than 20 contiguous amino acids of SEQ ID NO: 2 or SEQ ID NO: 17. Additional polypeptides includes those of formula (I) [ZNZPVSSBSFSYT]n and formula (II) [ZNUWOOBUFOYT]n. The invention further features vaccines including such polypeptides or conjugates and methods of vaccination against candidiasis or a staphylococcal infection of both using same. In addition, the invention features antibodies that bind to the polypeptides or conjugates, and methods of passive immunization using same.

Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.

Abstract: The disclosure provides cancer stem cells responsible for vascular mimicry, for use in stimulating immune response against a cancer. Methods for preparing and purifying the cancer stem cells are provided.

Abstract: Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth.

Abstract: The present disclosure provides reagents and methods for stimulating an immune response against an antigen associated with glioblastoma multiforme.

Abstract: Methods and products for producing an antigen specific immune response are provided. The methods involve administration of a caspase inhibitor to a subject.